- Urologie
- Open Access
- Published:
Traitement du cancer du testicule
Testicular cancer treatment
Andrologievolume 1, pages32–33 (1991)
Abstract
Significant advances have been achieved in testicular cancer treatment for the last 15 years. Almost 100% of the non seminomatous tumors seen at the precocious stages I and II are cured because of the efficacy of chemotherapy in relapses. For clinical stages I, tendancy is to survey after castration without lymphadenectomy. For advanced metastatic stages, platinum has changed chemotherapy performances, allowing to cure 75 to 80% of these patients. The results of a bad pronosis group with large tumor remain to be improved. Seminomas at a localized stage (the most frequent case) are cured by radiotherapy; at an advanced stage, they are as sensitive to chemotherapy as non seminomatous tumors.
Resume
Des progrès considérables ont été accomplis dans le traitement des cancers du testicule depuis une quinzaine d’années. Pour les tumeurs non séminomateuses de stade précoce (I et II) les taux de guérison avoisinent les 100% du fait de l’efficacité de la chimiothérapie de rattrapage des rechutes. Pour les stades cliniques I, la tendance est à la surveillance après castration sans curage. Pour les stades avancés métastasés, l’apparition du platinum a révolutionné les performances de la chimiothérapie qui permet de guérir 75 à 80% de ces patients. Il reste à améliorer les résultats d’un groupe de mauvais pronostic à forte masse tumorale. Les séminomes à un stade localisé (cas le plus fréquent) sont guéris par la radiothérapie; à un stade avancé, ils se montrent aussi sensibles à la chimiothérapie que les tumeurs non séminomateuses.
References
- 1.
Boyer M., Raghavan D., Harris PJ, Lietch J., Bleasel A., Walsh JC, Anderszon S., Tsang Chi S. Lack of late toxicity in patients treated with Cisplatin cotaining combination chemotherapy for metastatic testicular cancer. J. Clin. Oncol., 1990, 81: 21–26
- 2.
Donohue JP. Preservation of ejaculation, following nerve sparing retroperitoneal lymphadenectomy. J. Urol., 1988, 139: 206a
- 3.
Gressler VH, Levine LA, Vogelzang NJ. A third option in the management of patients with clinical stage I Non Seminomatous Germ Cell Tumor. J. Clin. Oncol., 1990, 8: 4–8
- 4.
Loehrer PJ, Williams SD, Einhorn LH. Testicular Cancer: the quest continues. J. Natl. Cancer Inst., 1988; 80: 1373–1382.
- 5.
Peckham M. Testicular Cancer. Reviews in oncology 1 (1988) No 1 (in Acta Oncologica, Vol 27, Fasc. 4)
- 6.
Pont J, Holt N, Kosal D, Machacek E., Kienzer H., Sulcker H., Honetz N. Risk adapted choice in stage I non seminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor. J. Clin. Oncol., 1990; 16–20
- 7.
Roth BJ, Greist A, Kubilis PS., Williams SD., Einvoorn LH. Cisplatin based combination chemiotherapy for disseminated germ cell tumors: long term follow up. J. Clin. Oncol., 1988; 6: 1239–1247
- 8.
Shibley L, Brown M, Schuttinga A., Rothenberg M., Whalem J. Cis platin based combination chemotherapy in the treatment of advanced — stage testicular cancer: cost benefit analysis. J. Natl. Cancer Inst., 1990; 82: 186–192
- 9.
Williams SD, Stablein DM, Einhorn LH et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N. Eng. J. Med., 1987; 317: 1433–1438
Author information
Affiliations
Corresponding author
Correspondence to Marcel Krulik.
Additional information
Rapport présenté au 8ème congrès de la SALF, Sousse Sept. 1990
Rights and permissions
About this article
Published
Issue Date
DOI
Key-words
- seminoma
- non seminomatous tumor
- chemotherapy
- radiotherapy
- surgery
- prognosis
- staging
Mots clés
- séminome
- tumeur non séminomateuse
- chimiothérapie
- radiothérapie
- chirurgie
- prognostic
- stade
